DAXXIFY® 100 Units
The next generation of botulinum toxin. Longer-lasting. Peptide-powered. Clinically proven.
Daxxify is a groundbreaking botulinum toxin type A formulation by Revance Therapeutics, and the first of its kind to use Peptide Exchange Technology™ (PXT). This proprietary innovation replaces the human serum albumin found in conventional botulinum toxins with a stabilising synthetic peptide (RTP004), resulting in a cleaner formulation and, most importantly, significantly extended duration of effect.
In the landmark SAKURA 1 and SAKURA 2 Phase 3 clinical trials, at least 50% of patients maintained none or mild frown lines for 24 weeks (6 months) or longer. For context, standard botulinum toxins typically last 3–4 months. That difference matters, for practitioners and patients alike.
What Is Daxxify Indicated For?
Daxxify is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (vertical frown lines between the eyebrows) in adult patients, associated with corrugator or procerus muscle activity.
How DAXXIFY® Works
Like all botulinum toxin type A products, DAXXIFY® works by blocking the release of acetylcholine at the neuromuscular junction, preventing targeted muscles from contracting and smoothing the overlying skin.
What sets DAXXIFY® apart is its unique RTP004 stabilising peptide. This synthetic excipient carries a high positive charge that forms a strong electrostatic bond with the toxin molecule. This enhanced binding:
Reduces diffusion away from the injection site for greater precision
Extends the duration of effect beyond conventional formulations
Eliminates the need for human serum albumin, making it the only botulinum toxin on the market that is albumin-free
The molecular weight of DAXXIFY® is 150 kDa, comparable to Xeomin (incobotulinumtoxinA), and is not detectable in the bloodstream at recommended doses.
Clinical Evidence, SAKURA Trials
DAXXIFY®’s efficacy is backed by robust Phase 3 data from the SAKURA clinical programme:
Clinical Finding Result
Onset of effect As early as Day 1, typically within 2 days
Improvement at Week 4 74% of patients showed improvement per both physician and patient assessment
Median duration of effect 24 weeks (6 months), significantly longer than standard neuromodulators
Skin texture improvement 64% of patients showed improvement at Week 2 (post-hoc Phase 2 analysis)
Immunogenicity No evidence of neutralising antibody formation observed during SAKURA trials
Key Product Details
Specification Detail
Active Ingredient DaxibotulinumtoxinA-lanm
Available Strengths 50-unit and 100-unit vials
Form Lyophilised powder for reconstitution
Reconstitution Sterile 0.9% sodium chloride, 8 units per 0.1 mL
Recommended Dose 40 units for glabellar lines
Reconstituted Stability Use within 72 hours; store at 6–8°C
Excipient RTP004 synthetic peptide (albumin-free)
Manufacturer Revance Therapeutics
⚠️ For use by qualified and trained aesthetic practitioners only. Units are not interchangeable between different botulinum toxin formulations. Always refer to full prescribing information before use.
Why Practitioners Choose DAXXIFY®
✅ Longer-lasting results, median duration of 6 months means fewer treatments per year for your patients, as few as 2 sessions annually
✅ Faster onset, visible improvement as early as Day 1, typically within 2 days
✅ Albumin-free formulation, no human or animal-derived proteins in the excipient
✅ Reduced diffusion, the electrostatic binding of RTP004 promotes localised action and precision dosing
✅ Strong clinical backing, FDA-approved, with data from the SAKURA 1, SAKURA 2, and SAKURA 3 Phase 3 trials
✅ Award-winning, recognised by TIME Best Inventions 2023, Cosmopolitan Holy Grail Beauty Award 2024, and Shape Skin Award 2025
Important Safety Information
DAXXIFY® is contraindicated in patients who:
Have known hypersensitivity to botulinum toxin type A or any excipients
Have an active infection at the proposed injection site
Have neuromuscular disorders such as myasthenia gravis or Lambert-Eaton syndrome
Are pregnant or breastfeeding (insufficient data available)
Common side effects include headache (reported in 5.9–7% of patients in SAKURA trials), localised bruising, erythema, or discomfort at the injection site. A minimum interval of 3 months between treatments is recommended.
For full prescribing information, refer to the DAXXIFY® FDA Label.
Order DAXXIFY® at AlphaBotox and enjoy free shipping on orders over €350. New customer? Get 15% off your first order, automatically applied at checkout.
